Apellis Pharmaceuticals is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 476 staff and has a trailing 12-month revenue of around $113 million.
How to buy Apellis Pharmaceuticals stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – APLS. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Apellis Pharmaceuticals stock price (NASDAQ: APLS)
Use our graph to track the performance of APLS stocks over time.Apellis Pharmaceuticals shares at a glance
Latest market close | $52.77 |
---|---|
52-week range | $33.32 - $70.00 |
50-day moving average | $49.71 |
200-day moving average | $52.43 |
Wall St. target price | $74.88 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-7.87 |
Buy Apellis Pharmaceuticals stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Apellis Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Apellis Pharmaceuticals price performance over time
Historical closes compared with the close of $52.77 from 2023-01-27
1 week (2023-01-23) | 4.27% |
---|---|
1 month (2022-12-30) | 2.05% |
3 months (2022-10-28) | -12.92% |
6 months (2022-07-29) | -6.24% |
1 year (2022-01-28) | 36.75% |
---|---|
2 years (2021-01-29) | 19.20% |
3 years (2020-01-30) | 27.13% |
5 years (2018-01-30) | 188.83% |
Apellis Pharmaceuticals financials
Revenue TTM | $113 million |
---|---|
Gross profit TTM | $-253,920,000 |
Return on assets TTM | -46.47% |
Return on equity TTM | -507.11% |
Profit margin | 0% |
Book value | $2.78 |
Market capitalisation | $5.7 billion |
TTM: trailing 12 months
Apellis Pharmaceuticals share dividends
We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.
Apellis Pharmaceuticals share price volatility
Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $33.32 up to $70. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 1.2264. This would suggest that Apellis Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Apellis Pharmaceuticals overview
Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases.
Apellis Pharmaceuticals in the news
Despite currently being unprofitable, Apellis Pharmaceuticals (NASDAQ:APLS) has delivered a 164% return to shareholders over 5 years
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Frequently asked questions
What percentage of Apellis Pharmaceuticals is owned by insiders or institutions?Currently 15.141% of Apellis Pharmaceuticals shares are held by insiders and 89.113% by institutions. How many people work for Apellis Pharmaceuticals?
Latest data suggests 476 work at Apellis Pharmaceuticals. When does the fiscal year end for Apellis Pharmaceuticals?
Apellis Pharmaceuticals's fiscal year ends in December. Where is Apellis Pharmaceuticals based?
Apellis Pharmaceuticals's address is: 100 Fifth Avenue, Waltham, MA, United States, 02451 What is Apellis Pharmaceuticals's ISIN number?
Apellis Pharmaceuticals's international securities identification number is: US03753U1060 What is Apellis Pharmaceuticals's CUSIP number?
Apellis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 03753U106
More guides on Finder
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert